Host-pathogen Interactions in Meningococcal Disease: Finding the Key That Fits the Lock

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Study Classification

OBSERVATIONAL

Study Start Date

2016-03-31

Study Completion Date

2019-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

At any time, around 10% of people carry meningococcal bacteria in the nose and throat, which can cause meningitis, blood poisoning and other serious illnesses. Most people carry these bacteria and never become ill, yet a very small proportion go on to develop these illnesses which can result in life long disabilities or death. The mechanism by which this happens is poorly understood and has been studied in various ways, usually focussing on the bacteria or on the individual, but none has given a definitive answer. This study will be the first of its kind and will assess the interaction between the host and the bacteria at the genetic level, through genetic mapping, helping us to understand what makes some people susceptible to this infection.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Investigating Meningococcal Vaccines in Adults

NCT02398396

Meningococcal Vaccines Meningococcal Infections Neisseria Meningitidis +1 more

COMPLETED NA

MenPF-1 - A New Vaccine Against Meningococcal Disease

NCT01640652

Serogroup B Meningococcal Disease

COMPLETED PHASE1

Safety and Immunogenicity Evaluation After One or Two Doses of Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Infants and Toddlers

NCT00667602

Meningococcal Meningitis

COMPLETED PHASE3

Effect of Meningococcal Conjugate Vaccine on Meningococcal Carriage

NCT00119080

Meningitis

COMPLETED PHASE4

Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine in Infants and Toddlers When Administered Concomitantly With Routine Pediatric Vaccines in the United Kingdom

NCT03632720

Healthy Volunteers (Meningococcal Infection)

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

At any time, around 10% of people carry meningococcal bacteria in the nose and throat, which can cause meningitis, blood poisoning and other serious illnesses. Most people carry these bacteria and never become ill, yet a very small proportion go on to develop these illnesses which can result in life long disabilities or death. The mechanism by which this happens is poorly understood and has been studied in various ways, usually focussing on the bacteria or on the individual, but none has given a definitive answer. This study will be the first of its kind and will assess the interaction between the host and the bacteria at the genetic level, through genetic mapping, helping us to understand what makes some people susceptible to this infection.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Meningitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

OTHER

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

meningitis cases

any individual with culture-confirmed IMD in England from 01 September 2015 to 31 August 2019 with written informed consent from the individual, the parent (for children aged \<16 years) or next-of-kin (for non-survivors)

Meningitis cases

Intervention Type OTHER

None - blood draw only

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Meningitis cases

None - blood draw only

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* any individual with culture-confirmed IMD in England from 01 September 2015 to 31 August 2019
* written informed consent from the individual, the parent (for children aged \<16 years) or next-of-kin (for non-survivors)

Exclusion Criteria

* Critically-ill patients and/or their family member will be only approached when the patient starts recovering from their illness or after they are deceased, on the advice of their clinical team.

Eligible Sex

ALL

Accepts Healthy Volunteers

No